GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (WBO:MYL) » Definitions » Cyclically Adjusted PS Ratio

Viatris (WBO:MYL) Cyclically Adjusted PS Ratio : 0.46 (As of May. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Viatris Cyclically Adjusted PS Ratio?

As of today (2024-05-26), Viatris's current share price is €9.65. Viatris's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €20.79. Viatris's Cyclically Adjusted PS Ratio for today is 0.46.

The historical rank and industry rank for Viatris's Cyclically Adjusted PS Ratio or its related term are showing as below:

WBO:MYL' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.37   Med: 1.63   Max: 5.23
Current: 0.46

During the past years, Viatris's highest Cyclically Adjusted PS Ratio was 5.23. The lowest was 0.37. And the median was 1.63.

WBO:MYL's Cyclically Adjusted PS Ratio is ranked better than
87.21% of 743 companies
in the Drug Manufacturers industry
Industry Median: 2.11 vs WBO:MYL: 0.46

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Viatris's adjusted revenue per share data for the three months ended in Mar. 2024 was €2.787. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €20.79 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Viatris Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Viatris's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Cyclically Adjusted PS Ratio Chart

Viatris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.99 0.90 0.61 0.49 0.48

Viatris Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.43 0.43 0.48 0.53

Competitive Comparison of Viatris's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viatris's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Viatris's Cyclically Adjusted PS Ratio falls into.



Viatris Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Viatris's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=9.65/20.79
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Viatris's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.787/131.7762*131.7762
=2.787

Current CPI (Mar. 2024) = 131.7762.

Viatris Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 3.403 100.560 4.459
201409 4.070 100.428 5.340
201412 4.215 99.070 5.607
201503 3.897 99.621 5.155
201506 4.049 100.684 5.299
201509 4.672 100.392 6.133
201512 4.483 99.792 5.920
201603 3.861 100.470 5.064
201606 4.471 101.688 5.794
201609 5.202 101.861 6.730
201612 5.775 101.863 7.471
201703 4.736 102.862 6.067
201706 4.909 103.349 6.259
201709 4.667 104.136 5.906
201712 5.108 104.011 6.472
201803 4.213 105.290 5.273
201806 4.656 106.317 5.771
201809 4.749 106.507 5.876
201812 5.239 105.998 6.513
201903 4.288 107.251 5.269
201906 4.895 108.070 5.969
201909 5.210 108.329 6.338
201912 5.530 108.420 6.721
202003 4.585 108.902 5.548
202006 4.689 108.767 5.681
202009 4.874 109.815 5.849
202012 3.486 109.897 4.180
202103 3.082 111.754 3.634
202106 3.143 114.631 3.613
202109 3.180 115.734 3.621
202112 3.177 117.630 3.559
202203 3.137 121.301 3.408
202206 3.200 125.017 3.373
202209 3.381 125.227 3.558
202212 2.996 125.222 3.153
202303 2.889 127.348 2.989
202306 3.005 128.729 3.076
202309 3.059 129.860 3.104
202312 2.906 129.419 2.959
202403 2.787 131.776 2.787

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Viatris  (WBO:MYL) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Viatris Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Viatris's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Viatris (WBO:MYL) Business Description

Industry
Traded in Other Exchanges
Address
1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris (WBO:MYL) Headlines

No Headlines